Biotech Values

[DewDiligence]

RVNC 2016 news flow and 12/31/15 cash balance:

http://www.sec.gov/Archives/edgar/data/1479290/000147929016000020/rvncex9911716.htm

• RT001 (Topical)—Phase 3 Program for the Treatment of Lateral Canthal (Crow’s Feet) Lines: The company is actively enrolling patients in its REALISE 1 Phase 3 trial to evaluate the safety and efficacy of a single, bilateral administration of RT001 topical compared to placebo in patients with moderate to severe crow’s feet. The company plans to release 28-day interim results from this Phase 3 trial in the first half of 2016. In the second half of 2016, Revance then plans to initiate a second Phase 3 efficacy trial and a long-term safety study.

• RT001 (Topical)—Phase 2 Trial for the Treatment of Axillary Hyperhidrosis (Excessive Underarm Sweating): The company plans to complete its current Phase 2 trial of RT001 topical for the treatment of axillary hyperhidrosis in the first quarter of 2016 and then expects to initiate an additional, larger Phase 2 hyperhidrosis trial in 2016.

• RT002 (Injectable)—Phase 3 Program for the Treatment of Glabellar (Frown) Lines: Revance plans to report the final results of the BELMONT Phase 2 active comparator clinical trial for the treatment of glabellar (frown) lines and conduct an End-of-Phase 2 meeting with the US Food and Drug Administration in the first half of 2016. The company expects to initiate a Phase 3 clinical program in the second half of 2016, comprised of two Phase 3 efficacy trials and a long-term safety study.

• RT002 (Injectable)—Phase 2 Trial for the Treatment of Cervical Dystonia: The company’s Phase 2 dose-escalating clinical trial of RT002 injectable for the treatment of cervical dystonia is underway, with interim results expected in the first half of 2016.

--
The company now expects its December 31, 2015 cash and investments balance to exceed $250 million. Revance’s prior guidance of more than $245 million was provided on November 9, 2015.